Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors

Response resistance to the immune checkpoint blockade (ICB) immunotherapy remains a major clinical challenge that may be overcome through the rational combination of ICB and specific targeted therapeutics. One emerging combination strategy is based on sensitizing ICB-refractory tumors with antagonis...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahmy, Sharif, Mishra, Sanket J., Murphy, Sean, Blagg, Brian S. J., Lu, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630337/
https://www.ncbi.nlm.nih.gov/pubmed/36341371
http://dx.doi.org/10.3389/fimmu.2022.1005045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630337/
https://www.ncbi.nlm.nih.gov/pubmed/36341371
http://dx.doi.org/10.3389/fimmu.2022.1005045

Ejemplares similares